Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2651170 | 0.83 | GABRA1 (0.42) | FGFR1HPGDALDH1A1 | |
| SCHEMBL2652727 | 0.82 | GABRA1 (0.51) | FGFR1HPGDALDH1A1 | |
| SCHEMBL2668063 | 0.81 | HPGD (0.52) | MEN1KMT2AFGFR1HPGDALDH1A1 | |
| SCHEMBL2651970 | 0.81 | FGFR1 (0.45) | FGFR1HPGDALDH1A1 | |
| SCHEMBL2651858 | 0.81 | GABRA1 (0.40) | FGFR1HPGDALDH1A1 | |
| SCHEMBL8233271 | 0.79 | FGFR1 (0.46) | MEN1KMT2AFGFR1HPGDALDH1A1 | |
| SCHEMBL2666424 | 0.79 | FGFR1 (0.46) | MEN1KMT2AFGFR1HPGDALDH1A1 | |
| SCHEMBL1616888 | 0.79 | FGFR1 (0.46) | MEN1KMT2AFGFR1HPGDALDH1A1 | |
| SCHEMBL2652008 | 0.79 | FGFR1 (0.46) | MEN1KMT2AFGFR1HPGDALDH1A1 | |
| SCHEMBL12415695 | 0.78 | FGFR1 (0.45) | MEN1KMT2AFGFR1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851490-B2 | Benzimidazole derivatives and their use for modulating the GABAA receptor complex | NEUROSEARCH A/S (DK) | 2010-12-14 | — | — | US | disclosed |
| EP-1877052-B1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH AS (DK) | 2009-07-22 | — | — | EP | disclosed |
| US-20090036493-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA Alpha Receptor Complex | ANIONA APS (DK) | 2009-02-05 | — | — | US | disclosed |
| EP-1877052-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006108800-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036493-A1 | Benzimidazole Derivatives and Their Use for Modulating the GABA Alpha Receptor Complex | GABRB2, GABRB1, GABRB3 | MEN1 4473/4885KMT2A 1674/4885FGFR1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.